 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | National Tuberculosis Control Program |
| Street 1: | P.O.Box KB926 Korlebu Accra |
| Street 2: | |
| City: | Accra |
| Province: | Greater Accra |
| Post Code: | 00233 |
| Country: | Ghana |
| Phone: | 0302 660023 |
| Email: | ahmed.iddrisu@ghsmail.org |
| Web Site: | http://www.ghsmail.org |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Countries |
| Organization Type - Primary: | Governmental Organization |
| Organization Type - Secondary: | None |
| Is your organization legally registered in your country: | Yes |
| Organization Reach: | International |
| Organization Description: | |
| Global Sustainable Development Program | |
| Total number of staff in your organization: | 1 - 5 |
| Number of full-time staff who are directly involved with TB: | 1 - 5 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 11 - 25 |
| What is your organization's annual budget (USD) dedicated to TB? | $1 MIL-$10 MIL |
| How did you hear about the Stop TB Partnership: | Involvement in TB control provision |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | Ghana |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Advocacy communication and Social Mobilization. Monitoring and evaluation. Training and workshops Research and surveillance |
|
Geographical Reach | |
| Which country is your headquarters located in: | Ghana |
| Which WHO region is the main focus of your work: | African |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Ghana |
Specializations | |
|
Advocacy, communication and social mobilization Delivery of health services and care Provision of drugs, diagnostics and commodities Research and Development Technical Assistance |
Specializations in Countries | |
| Advocacy, communication and social mobilization | Ghana |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
DOTS Expansion and Enhancement: 1. Political commitment with increased and sustained financing Legislation, planning, human resources, management, training 2. Case detection through quality-assured bacteriology Strengthening TB laboratories, drug resistance surveillance 3. Standardized treatment with supervision and patient support TB treatment and programme management guidelines, International Standards of TB Care (ISTC), PPM, Practical Approach to Lung Health (PAL), community-patient involvement 4. An effective drug supply and management system Availability of TB drugs, TB drug management, Global Drug Facility (GDF), Green Light Committee (GLC) 5. Monitoring and evaluation system and impact measurement TB recording and reporting systems, Global TB Control Report, data and country profiles, TB planning and budgeting tool, WHO epidemiology and surveillance online training Drug-Resistant TB: Anti-tuberculosis (TB) drug resistance is a major public health problem that threatens progress made in TB care and control worldwide. Drug resistance arises due to improper use of antibiotics in chemotherapy of drug-susceptible TB patients. This improper use is a result of a number of actions including, administration of improper treatment regimens and failure to ensure that patients complete the whole course of treatment. Essentially, drug resistance arises in areas with weak TB control programmes. A patient who develops active disease with a drug-resistant TB strain can transmit this form of TB to other individuals. TB-HIV: The risk of developing tuberculosis (TB) is estimated to be between 20-37 times greater in people living with HIV than among those without HIV infection. In 2010, there were 8.8 million new cases of TB, of which 1.1 million were among people living with HIV. In response to demands from countries, WHO recommends 12 TB/HIV collaborative activities, including the Three I's for HIV/TB. The WHO HIV/AIDS and TB Departments and their partners, including community groups, work collaboratively on joint HIV/TB advocacy, policy development and implementation in countries. WHO also develops and promotes tools and guidelines to support countries in improving their TB/HIV collaborative action in order to achieve universal access to HIV and TB prevention, care and treatment services for all people in need Laboratory Strengthening: In every country where I-TECH works, health needs and program goals are best met when local laboratories and services are reliable, consistent, and readily available. To deliver potentially life-saving results quickly and efficiently, laboratories must be well equipped and staffed with trained experts. Strengthened laboratories also have the capacity to share information with other laboratories worldwide, allowing them to become part of a global community and extending their resources. Current Laboratory Team activities include pre-service curriculum development; in-service training; support of ministries of health in strategic planning; implementation of laboratory information systems with I-TECH’s Informatics Team; and implementation of new laboratory technologies. As the team expands its scope, members will continue to prioritize these activities while responding to needs of partnering agencies as they arise. New Diagnostics: The New Diagnostics Working Group is a one of the seven Working Groups of the Stop TB Partnership. It aims at supporting the Partnership in its goal of elimination of TB, in particular by promoting the development and adoption of new diagnostic tools. The New Diagnostics Working Group is a network of experts representing stakeholders from academia, government, industry, NGOs and the patient community. In a drive to expand adoption of the Xpert® MTB/RIF test, the Bill & Melinda Gates Foundation, the United States President’s Emergency Plan for AIDS Relief (PEPFAR), the United States Agency for International Development (USAID) and UNITAID recently announced their agreement to significantly reduce the cost of this rapid TB diagnostic tool in 145 high-burden countries. This agreement will fund the buy-down of the Xpert MTB/RIF cartridges from $16.86 to $9.98. New TB Drugs: we highlight an interview with Dr. Douglas Lowrie, a Senior Research Fellow at Fudan University’s Shanghai Public Health Clinical Center in China. He discusses the extent of the problem of TB in China and innovative research on enhancing TB treatment using immunotherapeutic vaccines. New TB Vaccines: Safe and effective tuberculosis (TB) vaccines are urgently needed. TB continues to take the lives of almost one and a half million people per year and devastates the lives of millions more. New TB vaccines are an urgent part of a comprehensive plan to control and ulimately eliminate TB. Over the past decade, researchers have made significant progress in TB vaccine development, and a dozen TB vaccine candidates are now being evaluated in clinical trials.Developing new TB vaccines is a costly, complex and time-consuming undertaking that requires a coordinated global effort. Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade provides a strategy to develop more effective TB vaccines as quickly and cost-effectively as possible. It was developed in consultation with stakeholders from the TB vaccine research community and outlines the major scientific challenges and priorities, critical activities and crucial questions that need to be addressed to develop these life-saving vaccines. Fundamental Research: In contrast to profit-driven research, such as most applied research and development work, fundamental research is usually unpredictable in terms of its course and outcomes. Fundamental research requires a special way of thinking that often combines seemingly unrelated facts and explores unknown fields necessary to make new discoveries. It is for this reason that cutting-edge, fundamental research is frequently multidisciplinary in nature. Standardised methods, techniques and procedures that were developed to solve relatrively clearly defined problems are generally not sufficient in fundamental research. A stroke of genius or an unconventional idea is usually needed to increase understanding of the environments, both natural and man-made, in which we live today. The talents necessary in fundamental research may be largely innate, but they do need a stable environment to develop. Operational Research: The Union's strategy for combating TB and HIV with coordinated and integrated methods includes measures and resources to scale up participating countries' health-care systems, capacity building and drug and equipment procurement. In addition to specific project work, The Union achieves these objectives through: technical assistance (TA) missions through which HIV and TB/HIV experts provide support to national governments and ministries of health |
|
Declaration | |
| Declaration of interests: Mobile workers are usually in regular or constant transit, sometimes in (regular) circulatory patterns and often spanning two or more countries, away from their habitual or established place of residence for varying periods of time. Morbidity: The state of being ill or having a disease. Mortality: An individual’s death or decease; loss of life. Multidrug-resistant tuberculosis (MDR-TB): MDR-TB is a specific form of drug-resistant tuberculosis, due to a bacillus that is resistant to at least isoniazid and rifampicin, the two most powerful antituberculosisdrugs. Post-exposure prophylaxis (PEP): PEP refers to antiretroviral medicines that are taken after exposure or possible exposure to HIV. The exposure may be occupational, as in a needle stick injury, or nonoccupational, as in unprotected sex with a person living with HIV. Pre-exposure prophylaxis (PrEP): PrEP refers to antiretroviral medicines prescribed before exposure or possible exposure to HIV. PrEP strategies under evaluation increasingly involve the addition of a postexposure dosage. ‘Positive health, dignity, and prevention’: Previously referred to as ‘positive prevention’, it encompasses strategies to protect sexual and reproductive health and delay HIV disease progression. It includes individual health promotion, access to HIV and sexual and reproductive health services, community participation, advocacy and policy change. Prevention of mother-to-child transmission (PMTCT): PMTCT refers to a four-pronged strategy to prevent new HIV infections in children and keep mothers alive and families healthy. The four prongs are: halving HIV incidence in women; reducing the unmet need for family planning; providing antiretroviral prophylaxis to prevent HIV transmission during pregnancy, labour and delivery, and breastfeeding; and providing care, treatment and support for mothers and their families. Some countries prefer to use the term ‘vertical transmission’ to acknowledge the role of the father/male sexual partner in transmitt | |
| Application date: | October 15, 2012 |
| Last updated: | February 20, 2013 |